Hansa Biopharma GBS has advanced to become another value driver - Redeye

Imflifidase shows robust efficacy results in phase 2 among patients with severe GBS. This is an orphan indication, and GBS is an acute disease in patients that tends to become non-ambulatory within weeks rapidly. If approved, Imflifidase will expand into a dynamic market. We increase our base case to SEK 130 from 125 (Bull SEK 250, Bear SEK 15).

Länk till analysen i sin helhet: https://www.redeye.se/research/1065964/hansa-biopharma-gbs-has-advanced-to-become-another-value-driver?utm_source=finwire&utm_medium=RSS